Physician profile
Gerald Thomas Ware
NPI 1851373484
$2,539.33
in general payments reported to CMS, 2019-2025
18 companies · $398 in 2025
The $398 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $106 · 2021: $161 · 2022: $363 · 2023: $232 · 2024: $936 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373 · Travel and Lodging: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.95 |
| Travel and Lodging | $192.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.06 | 2019-2025 | Ozurdex |
| Alcon Vision LLC | $417.55 | 2024 | |
| Alimera Sciences, INC. | $369.66 | 2019-2024 | Yutiq, Iluvien |
| Regeneron Healthcare Solutions, INC. | $284.26 | 2019-2025 | Eylea Hd |
| Allergan, INC. | $222.40 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $195.58 | 2022-2025 | Acthar |
| Genentech USA, INC. | $156.45 | 2019-2025 | Vabysmo |
| Optos, INC. | $100.00 | 2022 | |
| Astellas Pharma US INC | $94.65 | 2024-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $78.59 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $63.89 | 2025 | Iluvien, Purified Cortrophin Gel |
| Carl Zeiss Meditec USA, INC. | $28.33 | 2021 | |
| Apellis Pharmaceuticals, INC. | $20.71 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $19.58 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $16.84 | 2019 | |
| Heidelberg Engineering, INC. | $14.86 | 2025 | Spectralis |
| Vyera Pharmaceuticals, LLC | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.